Eli Lilly has signed a Memorandum of Understanding (MOU) with the Ministry of Health and Welfare, officially announcing an investment of a total of $500 million (approximately 740 billion KRW) in the Korean pharmaceutical and bio-industry over five years, starting from 2026. The core of this initiative is 'Lilly Gateway Labs Korea' – a hub supporting open innovation startups, designed to connect Korean bio-ventures to global pipelines. 97% of the investment ($486 million) will be allocated to global clinical trials within Korea. This allocation of 97% of the investment to clinical trials is not merely financial support. It signifies Lilly's designation of Korea as a substantive global R&D hub. Lilly possesses world-leading pipelines in obesity (GLP-1), Alzheimer's disease, and immunology. Increased participation in clinical trials within Korea will simultaneously build patient data, clinical infrastructure, and medical professional capabilities. This will also lead to the co-growth of the K-CRO industry and CDMO demand. Lilly's move positions it in contrast to AstraZeneca's $14 billion investment in China. This is a strategic decision to choose Korea as its Asian clinical hub instead of China. Aligned with the government's goal of 'Korea becoming one of the top 5 global bio-powerhouses,' discussions for joint clinical trials and technology exports with companies like Hanmi Pharmaceutical, Yuhan Corporation, and SK Biopharmaceuticals are also gaining momentum.